Showing results (921-930 of 1,033) with videos related to

Sort By:
Pageof 104
The Lancet. Respiratory Medicine|January 16, 2019
Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysisLaveena Munshi, Allan Walkey, Ewan Goligher, et al.
The Lancet. Respiratory Medicine|August 26, 2014
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trialsAlan F Barker, Anne E O'Donnell, Patrick Flume, et al.
The Lancet. Respiratory Medicine|June 3, 2023
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Simon Lambden, Tom Fivez, et al.
The Lancet. Respiratory Medicine|May 19, 2026
Effects of inflammatory phenotypes in acute respiratory distress syndrome on mortality and partitioning of lung and chest wall mechanics in patients in the USA and Canada: a retrospective cohort studyJoris Pensier, Maxime Fosset, Béla-Simon Paschold, et al.
The Lancet. Respiratory Medicine|March 23, 2023
Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3)Jean Reignier, Gaetan Plantefeve, Jean-Paul Mira, et al.
The Lancet. Respiratory Medicine|June 5, 2026
Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment-an expert group consensus statementJoshua J Solomon, Philippe Dieudé, Scott M Matson, et al.
The Lancet. Respiratory Medicine|June 9, 2026
Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trialKate Leslie, Jai N Darvall, Matthew T V Chan, et al.
The Lancet. Respiratory Medicine|April 27, 2026
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyAmelia Shoemark, Emma D Johnson, Morven Shuttleworth, et al.
The Lancet. Respiratory Medicine|May 7, 2026
Respiratory infections due to human common cold coronaviruses, SARS-CoV, MERS-CoV, and SARS-CoV-2: epidemiology, pathogenesis, clinical features, diagnostics, therapeutics, and vaccine landscapesAlimuddin Zumla, David S Hui, Malik Peiris, et al.
The Lancet. Respiratory Medicine|April 24, 2026
Contributors to the heterogeneity of response to CFTR modulatorsDamian G Downey, Claire Houston, Nicole Mayer-Hamblett, et al.
Pageof 104